Patents Examined by Bong-Sook Baek
  • Compositions and methods for increasing dextromethorphan plasma levels and related pharmacodynamic effects
    Patent number: 9314462
    Abstract: This disclosure relates to methods of increasing dextromethorphan plasma levels comprising co-administering hydroxybupropion, or a prodrug thereof, and dextromethorphan to a human being in need of treatment with dextromethorphan. Dosage forms, drug delivery systems, and methods related to dextromethorphan and hydroxybupropion or a prodrug of bupropion are also disclosed.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: April 19, 2016
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Bupropion as a modulator of drug activity
    Patent number: 9278095
    Abstract: This disclosure relates to methods administering bupropion or a prodrug thereof in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion or a prodrug of bupropion are also disclosed.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: March 8, 2016
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • 5-nonyloxytryptamine and related intracellular PH acidifiers for the treatment and prevention of cancer
    Patent number: 9278924
    Abstract: Provided herein are compositions for lowering intracellular pH in a cell or population of cells from a subject comprising contacting the cell or population of cells with a therapeutically effective amount of 5-nonyloxytryptamine or a pharmaceutically acceptable salt, solvate, stereoisomer, or derivatives thereof. These compounds are useful for acidification of cells, including cancer cells, which induces apoptosis and cell necrosis. Methods of use of these compounds, including in pharmaceutical compositions in conjunction with other biologically active agents, in treatment of cancers, including glioblastoma and related neuronal cancers are also included.
    Type: Grant
    Filed: October 25, 2012
    Date of Patent: March 8, 2016
    Assignee: The Johns Hopkins University
    Inventor: Eli Eliyahu Bar
  • Efficacy in treating bacterial infections
    Patent number: 9259415
    Abstract: The present disclosure relates to molecules which function as selective modulators (i.e., inhibitors and agonists) of the Ras-homologous (Rho) family of small GTPases and, in particular, CDC42 GTPase, and their use to treat bacterial infection including systemic infection from sources such as Staphylococcus aureus.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: February 16, 2016
    Assignees: Ball State Innovation Corporation, STC.UNM
    Inventors: Susan A. McDowell, Robert E. Sammelson, Larry A. Sklar, Mark K. Haynes
  • Derivatives of nicotinic acid N-oxide, their preparation and their use as inhibitors of enzyme 3-hydroxyanthranilate-3, 4-dioxygenase
    Patent number: 9260394
    Abstract: A derivative of nicotinic acid N-oxide is described having formula (I): that acts as inhibitor of enzyme 3-hydroxyanthranilate-3,4-dioxygenase (3HAO), and is thus able to reduce QUIN biosynthesis in vivo under excitotoxic or pathological conditions, said compound being at the same time also chemically stable towards auto-oxidation.
    Type: Grant
    Filed: January 19, 2011
    Date of Patent: February 16, 2016
    Assignees: UNIVERSITY OF MARYLAND, BALTIMORE, UNIVERSITA' DELGI STUDI DI PARMA
    Inventors: Robert Schwarcz, Gabriele Costantino, Laura Amori
  • Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of hematological dyscrasias and cancer of an organ
    Patent number: 9248114
    Abstract: The present invention refers to the use of a compound of Formula (I?) or pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of hematological dyscrasias, including myelodysplastic syndromes (MDSs) and for improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy. In addition, it relates to the use of a compound of formula (I?) for the treatment and/or prophylaxis of cancer of an organ.
    Type: Grant
    Filed: August 12, 2013
    Date of Patent: February 2, 2016
    Assignee: Action Medicines, S.L.
    Inventors: Pedro Cuevas Sanchez, Guillermo Gimenez Gallego, Inigo Saenz De Tejada Morgan, Javier Angulo Frutos, Rosa Maria Lozano Puerto, Antonio Romero Garrido, Serafin Valverde Lopez
  • Method and compositions for treatment or prevention of inflammatory conditions
    Patent number: 9241932
    Abstract: Pharmaceutical compositions and methods for treating or preventing an inflammatory condition in a patient are disclosed. The pharmaceutical compositions and methods include the use of vincamine or a vincamine derivative, either alone or in combination with one or more additional therapeutic agents, including a steroid (preferably a corticosteroid), an angiotensin II receptor (type 1) antagonist, an angiotensin-converting enzyme (ACE) inhibitor, and a non-steroidal anti-inflammatory drug.
    Type: Grant
    Filed: February 26, 2014
    Date of Patent: January 26, 2016
    Assignee: UNIVERSITY OF ROCHESTER
    Inventors: Chen Yan, Jian-Dong Li, Bradford Berk, Kye-Im Jeon, Xiangbin Xu
  • Enhanced bimatoprost ophthalmic solution
    Patent number: 9241918
    Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
    Type: Grant
    Filed: March 4, 2010
    Date of Patent: January 26, 2016
    Assignee: Allergan, Inc.
    Inventors: Chin-Ming Chang, James N. Chang, Rhett M. Schiffman, R. Scott Jordan, Joan-En Chang-Lin
  • Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
    Patent number: 9238032
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: January 19, 2016
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Antiviral compounds
    Patent number: 9233974
    Abstract: The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: January 12, 2016
    Assignee: Gilead Sciences, Inc.
    Inventors: John O. Link, Jeromy J. Cottell, Teresa Alejandra Trejo Martin, Elizabeth M. Bacon
  • Pharmacological treatment of Parkinson's disease
    Patent number: 9226904
    Abstract: The present invention relates to the co-administration of two neurotransmitter agonists to patients with motor disorders, for the purpose of symptom reduction. In particular the present invention provides methods and compositions for alleviation of akinesia, rigidity and/or tremor associated with Parkinson's disease.
    Type: Grant
    Filed: March 24, 2010
    Date of Patent: January 5, 2016
    Assignee: The United States of America as Represented by the Department of Veterans Affairs
    Inventors: William A. Wolf, Erik D. Istre
  • Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan
    Patent number: 9205083
    Abstract: This disclosure relates to methods of improving the efficacy of dextromethorphan, or providing beneficial pharmacokinetic effects to dextromethorphan, comprising co-administering erythrohydroxybupropion, or a prodrug thereof, and dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan and erythrohydroxybupropion or a prodrug of erythrohydroxybupropion are also disclosed.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: December 8, 2015
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects
    Patent number: 9198905
    Abstract: This disclosure relates to methods of decreasing dextrorphan plasma levels comprising co-administering hydroxybupropion, or a prodrug thereof, and dextromethorphan to a human being in need of treatment with dextromethorphan. Dosage forms, drug delivery systems, and methods related to dextromethorphan and hydroxybupropion or a prodrug of bupropion are also disclosed.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: December 1, 2015
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Heterocyclylamines as PI3K inhibitors
    Patent number: 9199982
    Abstract: The present invention provides heterocyclylamine derivatives of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: December 1, 2015
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Yun-Long Li, Andrew P. Combs, Eddy W. Yue, Brent Douty, Song Mei
  • Aryl-quinoline derivatives
    Patent number: 9199938
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6 and n are as described herein, compositions including the compounds and methods of using the compounds. The present compounds are useful as fatty-acid binding protein (FABP) 4 and/or 5 inhibitors and may be used for the treatment or prophylaxis of lipodystrophy, type 2 diabetes, dyslipidemia, atherosclerosis, liver diseases involving inflammation, steatosis and/or fibrosis, such as non-alcoholic fatty liver disease, in particular non-alcoholic steatohepatitis, metabolic syndrome, obesity, chronic inflammatory and autoimmune inflammatory diseases.
    Type: Grant
    Filed: November 1, 2012
    Date of Patent: December 1, 2015
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Simona M. Ceccarelli, Aurelia Conte, Holger Kuehne, Bernd Kuhn, Werner Neidhart, Ulrike Obst Sander, Markus Rudolph
  • Composition for eyelash growth
    Patent number: 9168212
    Abstract: The present invention relates to a pharmaceutical or cosmetic composition and a method for promoting eyelash growth, wherein nipradilol or pharmaceutically or cosmetically acceptable salts thereof are used as active ingredients. The composition of the invention may comprise prostaglandin F2? analogs.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: October 27, 2015
    Assignee: SK CHEMICALS CO., LTD.
    Inventors: Sang-hwan Kang, Keun-Ho Ryu, DongChul Shin, Bong-yong Lee
  • Bupropion as a modulator of drug activity
    Patent number: 9168234
    Abstract: This disclosure relates to methods administering bupropion or a prodrug thereof in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion or a prodrug of bupropion are also disclosed.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: October 27, 2015
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Caffeinated compounds and compositions for treatment of amyloid diseases and synucleinopathies
    Patent number: 9169255
    Abstract: Compounds and their pharmaceutically acceptable salts for treatment of ?-amyloid diseases, such as observed in Alzheimer's disease and synucleinopathies, such as Parkinson's disease.
    Type: Grant
    Filed: October 10, 2012
    Date of Patent: October 27, 2015
    Assignee: Proteo Tech Inc.
    Inventors: Luke Esposito, Kelsey Hanson, Marisa C. Yadon, Thomas Lake, Alan D. Snow, Joel Cummings, Anil Kumar
  • Use for cannabinoid
    Patent number: 9168278
    Abstract: The invention relates to the use of one or more cannabinoids in the manufacture of medicaments for use in the treatment of diseases and conditions benefiting from neutral antagonism of the CB, cannabinoid receptor. Preferably the cannabinoid is tetrahydrocannabivarin (THCV). Preferably the diseases and conditions to be treated are taken from the group: obesity, schizophrenia, epilepsy, cognitive disorders such as Alzheimer's, bone disorders, bulimia, obesity associated with type II diabetes (non-insulin dependant diabetes) and in the treatment of drug, alcohol and nicotine abuse or dependency.
    Type: Grant
    Filed: November 15, 2005
    Date of Patent: October 27, 2015
    Assignee: GW Pharma Limited
    Inventors: Geoffrey William Guy, Roger Pertwee
  • Amine oxidase inhibitors
    Patent number: 9161922
    Abstract: A therapeutic agent for selectively inhibiting amine oxidases associated diseases and conditions in humans includes at least one compound selected from the group consisting of propargylamines, polypropargylamines, homopropargylamines, 4-substituted-2-butynylamines, 2- and 3-halloallylamines, pyrroline derivatives, cycloalkenyl branched primary amines, propargyl diamines, homopropargyl amines and diamines, allenyl amines and diamines, chloroallyl diamines, lysyne analogs, ?-haloamines, RF-substituted amines, RCi-substituted amines, and R3Si substituted amines.
    Type: Grant
    Filed: June 30, 2006
    Date of Patent: October 20, 2015
    Assignee: Case Western Reserve University
    Inventor: Lawrence M. Sayre